Pitavastatin; Atorvastatin
Проводит Kowa Research Europe
Страница компанииStudy of Pitavastatin 2 mg vs. Atorvastatin 10 mg and Pitavastatin 4 mg vs. Atorvastatin 20 mg (Following Up Titration) in Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00249249/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–75 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 830 чел. во всех странах исследования.
- Центров в реестре: 25 в 4 городах. Список — ниже на странице.
- Плановая дата окончания (11.2006) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 29
Критерии включения
- Males and females (age 18-75 years).
- Non-pregnant, non-lactating females
- Women of child bearing potential should use sustained contraceptive preparations or an approved mechanical contraceptive method.
- Eligible and able to participate and have given informed consent
- Must have been following a restrictive diet and does not eat or drink grapefruit
- Diagnosis of primary hypercholesterolemia or combined dyslipidemia
- Available for every clinic visit, which will occur in the morning.
Критерии невключения
- Homozygous familial hypercholesterolemia or familial hypoalphalipoproteinemia
- Conditions which may cause secondary dyslipidemia.
- Condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
- History of pancreatic injury or pancreatitis, or impaired pancreatic function/injury
- Liver injury
- Impaired renal function
- Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as clinically meaningful by the investigator
- Serum creatine kinase (CK) >5 x upper limit of the reference range (ULRR).
- Uncontrolled hypothyroidism
- Severe acute illness or severe trauma in the last 3 months
- Major surgery, 3 months prior to Visit 1
- Significant cardiovascular disease (CVD) prior to randomization
- Evidence of symptomatic heart failure, gross cardiac enlargement; significant heart block or cardiac arrhythmias. History of uncontrolled complex ventricular arrhythmias, uncontrolled atrial fibrillation/flutter or uncontrolled supraventricular tachycardias with a ventricular response rate of >100 beats per minute at rest.
- Left ventricular (LV) ejection fraction < 0.25
- History of symptomatic cerebrovascular disease
- Conditions at the discretion of the investigator
- Known HIV infection
- Poorly controlled or uncontrolled hypertension.
- Known muscular or neuromuscular disease of any type
- Neoplastic disease
- Drug abuse or continuous consumption of more than 65 mL pure alcohol per day
- Exposure to any investigational new drug within 30 days of study entry or ingestion of any drug known to be toxic to a major organ system
- Current or recent use of supplements known to alter lipid metabolism
- Hypersensitivity reactions to other HMG-CoA reductase inhibitors
- Concomitant medication not permitted
- Resistant to lipid-lowering medications. Known hypersensitivity or intolerance to any lipid lowering agent
- Excessive obesity
- Regular clinic attendance in the morning impractical
- Signs of mental dysfunction or other factors likely to limit ability to cooperate
Источник: ClinicalTrials.gov, NCT00249249 · запись обновлена в реестре 12 января 2010.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 11
- Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12 — Baseline to 12 weeks
Цель исследования
The purpose of this study is to compare the efficacy of pitavastatin with that of atorvastatin.
Где проходит
25 центров в 4 городах- Central Clinical Hospital 1 of RZD
- City Clinical Hospital 23
- City Clinical Hospital 64
- Federal State Institution Out-Patient Clinic 3 of Russian Federation of President’s Management
- Moscow City Clinical Hospital 68
- Moscow Regional Research Clinic Institute n.a.M.F.Vladimirov, Department of Therapy
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Department of Internal Diseases and Rheumatology based at City Clinica
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department # 1 based at City Clinical Hospital # 40
- State Educational Institution of Higher Professional Education “Moscow State University of Medicine and Dentistry of Federal Agency of Health Care and Social Development�, Hospital Therapy Department #1 based at City Clinical Hospital # 52
- State Educational Institution of Higher Professional Education “Russian State Medical University Federal Agency of Health Care and Social Development�, Department of Polyclinic Therapy based at Diagnostic Center # 1
- State Educational Institution of Higher Professional Education “Russian State Medical University of Federal Agency of Health Care and Social Development�, Department of Hospital Therapy #1 based at City Clinical Hospital #15, Cardiology Dept
- State Institution “Research Institute of Physical and Chemical Medicine� of Federal Agency of Health Care and Social Development, Laboratory of Clinical Cardiology based at Bauman City Hospital # 29
- State Institution “Russian Cardiology Research Complex� of Federal Agency of Health Care and Social Development, Myasnikov Clinical Cardiology Institute, Department of Hemodialysis and Plasmapheresis
- State Research Center for Preventive Medicine
- Central Medical Unit 122, St. Pb
- Clinical Hospital of Russian Academy of Sciences
- Consulting and Diagnostic Center 85
- Krestovsky Island Medical Institute
- St. Petersburg State Medical Institution “Out-patient Clinic # 109�
- St. Petersburg State Medical Institution “Pokrovskaya City Hospital�, Cardiology Department #2
- State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Chair and Department of Faculty Therapy
- State Educational Institution of Higher Professional Education, “Saint-Petersburg State Medical University n.a.Academician I.P.Pavlov of Federal Agency of Health Care and Social Development�, Institute of Cardiovascular Diseases
- СПб ГБУЗ «Городская Покровская больница»
Откуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00249249 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.